Market Newsdesk

ISELIN, N.J., April 02, 2025 (GLOBE NEWSWIRE) — Middlesex Water Company (NASDAQ: MSEX) announced today that its subsidiary, Tidewater Utilities, Inc. (TUI), completed its acquisition of the water system assets of the Town of Ocean View (TOV) in Sussex County, Delaware for $4.6 million.

“We are delighted to welcome Ocean View residents as our newest Tidewater customers,” said Bruce E. Patrick, President of TUI. “Maintaining the same water rates for all Ocean View residents during this transition is of the utmost importance to our team. We remain steadfast in our commitment of delivering clean, safe, reliable water service to our customers and remaining good community partners, just as we have for the past 17 years.”

The newly acquired TOV water system serves approximately 900 customers, who have been receiving water supply from TUI since the system was constructed in 2008. TUI also has been providing water distribution, meter reading, customer billing, and operational services to TOV during this time through its subsidiary, White Marsh Environmental Systems, Inc.

On February 19, 2025, the Delaware Public Service Commission approved TUI’s application to purchase the water assets of TOV and the right to provide water service to its existing customers.

“The sale of the Ocean View water distribution system to Tidewater Utilities presents benefits to the Town in several ways,” said Town Manager Carol Houck. “First and foremost, it ensures rate equity to our former water customers as Tidewater is subject to the regulations of the Delaware Public Service Commission. Likewise, Tidewater, a trusted partner to the Town for many years, will enhance customer service options to our former customers.”

Ocean View customers will receive additional information in the mail from TUI. Information also is available on the Tidewater website at www.TUIWater.com.

About Tidewater Utilities, Inc.

Tidewater Utilities, Inc. (“Tidewater”), a wholly owned subsidiary of Middlesex Water Company, is celebrating over 60-years of service to Delawareans. Tidewater is the largest private water supplier south of the Chesapeake & Delaware Canal in Delaware. The Company operates 172 active wells and 85 water treatment plants to serve approximately 62,000 customers in 480 separate communities in New Castle, Kent and Sussex County, Delaware.

About Middlesex Water Company

Middlesex Water Company (“Middlesex”) (NASDAQ: MSEX) is one of the nation’s premier investor-owned water and wastewater utilities. Established in 1897, Middlesex is a trusted provider of life-sustaining services to more than half a million people in New Jersey and Delaware. The company focuses on employee engagement, operational excellence, superior customer experience, investment in infrastructure, and selective and sustainable growth to deliver value to our customers, investors, and the communities we serve.

Media Contact:
Brian Hague, Vice President of Communications & Corporate Affairs
[email protected]
(732) 638-7549

Beamr will showcase its high-performance AV1 solutions, accelerated by NVIDIA GPUs, and with simple, competitive pricing, at the 2025 NAB Show in Las Vegas

HERZLIYA, Israel, April 02, 2025 (GLOBE NEWSWIRE) — Beamr Imaging Ltd. (NASDAQ: BMR), a leader in video optimization technology and solutions, will showcase its high-quality, cost-effective solution for AV1 (AOMedia Video 1) codec upgrades at the 2025 NAB Show (Meeting room SL1730MR), held in Las Vegas from April 5-9, along with a simple, competitive pricing plan.

Accelerated by NVIDIA GPUs and integrated with NVENC, an on-chip hardware-accelerated video encoder within NVIDIA GPUs, Beamr’s technology enables scalable, efficient AV1 upgrades with superior performance and high-quality results. While AV1 is an advanced video codec with improved image quality and superior compression, Beamr offers up to 30% additional compression.

Beamr provides AV1 encoding at a quarter of the cost or less compared to CPU-based solutions and other alternatives, bringing it in line with AVC (H.264) encoding costs. Readily accessible on cloud platforms such as Amazon Web Services (AWS) and Oracle Cloud Infrastructure (OCI), as well as private cloud or on-premises environments, Beamr simplifies AV1 adoption for companies working with videos at large scale – across media and entertainment, user-generated content, AI, and more.

“Available through straightforward, affordable pricing, Beamr removes barriers to AV1 adoption and allows users improved performance while significantly reducing video file sizes without sacrificing quality,” said Beamr CEO Sharon Carmel. “Our tests also show that optimized AV1 files by Beamr maintain full accuracy in AI applications such as facial recognition, action detection and enhancing machine learning models.”

AV1 is backed by tech giants within the Alliance for Open Media (AOMedia), and it is widely supported across most operating systems and web browsers, as well as recent smartphone models, smart TVs and more. Despite these advantages, complexity and high adoption costs have limited AV1’s usage.

Beamr’s video optimization technology is integrated with NVENC, and is available across multiple GPU platforms:

• Workstation GPUs: NVIDIA RTX PRO 6000 Blackwell Workstation Edition and NVIDIA RTX 4000 Ada Generation.
• Data Center GPUs: NVIDIA T4 Tensor Core, L4, L40, and L40S Tensor Core GPUs.

The NVENC SDK 12.1 release added an API that supports external control and enables users to tightly integrate hardware encoders with support for AV1.

Beamr video experts will be available throughout the NAB Show, April 5-9 in Las Vegas, to discuss cost-effective, high-quality, high-performance AV1 upgrades. For one-on-one meetings (Meeting room SL1730MR) please use this link.

For more details about Beamr’s AV1 offering, visit this link.

About Beamr

Beamr (Nasdaq: BMR) is a world leader in content-adaptive video optimization and modernization. The company serves top media companies like Netflix and Paramount. Beamr’s inventive perceptual optimization technology (CABR) is backed by 53 patents and won the Emmy® award for Technology and Engineering. The innovative technology reduces video file size by up to 50% while guaranteeing quality.

Beamr Cloud is a high-performance, GPU-based video optimization and modernization service designed for businesses and video professionals across diverse industries. It is conveniently available to Amazon Web Services (AWS) and Oracle Cloud Infrastructure (OCI) customers. Beamr Cloud enables video modernization to advanced formats such as AV1 and HEVC, and is ready for video AI workflows. For more details, please visit www.beamr.com

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements in this communication may include, among other things, statements about Beamr’s strategic and business plans, technology, relationships, objectives and expectations for its business, the impact of trends on and interest in its business, intellectual property or product and its future results, operations and financial performance and condition. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 4, 2025 and in subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of the date hereof and the Company undertakes no duty to update such information except as required under applicable law.

Investor Contact:

[email protected]

Agency Contact

Moe Lokat
Wall Street Communications
+44 7973 306039
[email protected] 

MONACO, April 02, 2025 (GLOBE NEWSWIRE) — Costamare Inc. (the “Company”) (NYSE: CMRE) has declared cash dividends of US $0.476563 per share on its 7.625% Series B Cumulative Redeemable Perpetual Preferred Stock (the “Series B Preferred Stock”) (NYSE: CMRE PR B), US $0.531250 per share on its 8.50% Series C Cumulative Redeemable Perpetual Preferred Stock (the “Series C Preferred Stock”) (NYSE: CMRE PR C) and US $0.546875 per share on its 8.75% Series D Cumulative Redeemable Perpetual Preferred Stock (the “Series D Preferred Stock”) (NYSE: CMRE PR D). The dividend for the Series B Preferred Stock, the Series C Preferred Stock and the Series D Preferred Stock is for the period from January 15, 2025 to April 14, 2025. The dividend will be paid on April 15, 2025 to all holders of record as of April 14, 2025 of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock.

The Company has also declared a quarterly dividend on its common stock of US $0.115 per share for the quarter ended March 31, 2025. The dividend for the common stock is payable on May 6, 2025, to holders of record of common stock as of April 17, 2025.

The declaration of a dividend is subject to the discretion of the Board of Directors of the Company, and accordingly will depend on, among other things, the Company’s earnings, financial condition and cash requirements and availability, the Company’s ability to obtain debt and equity financing on acceptable terms as contemplated by the Company’s growth strategy, the restrictive covenants in the Company’s existing and future debt instruments and global economic conditions.

About Costamare Inc.

Costamare Inc. is one of the world’s leading owners and providers of containerships and dry bulk vessels for charter. The Company has 51 years of history in the international shipping industry and a fleet of 68 containerships, with a total capacity of approximately 513,000 TEU and 38 owned dry bulk vessels with a total capacity of approximately 3,016,000 DWT (including one vessel we have agreed to sell). The Company also has a dry bulk operating platform which charters in/out dry bulk vessels, enters into contracts of affreightment, forward freight agreements and may also utilize hedging solutions. Furthermore, the Company participates in a lease financing business. The Company’s common stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock trade on the New York Stock Exchange under the symbols “CMRE”, “CMRE PR B”, “CMRE PR C” and “CMRE PR D”, respectively.

Forward-Looking Statements

This press release contains “forward-looking statements”. In some cases, you can identify these statements by forward-looking words such as “believe”, “intend”, “anticipate”, “estimate”, “project”, “forecast”, “plan”, “potential”, “may”, “should”, “could” and “expect” and similar expressions. These statements are not historical facts but instead represent only the Company’s belief regarding future results, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that actual results may differ, possibly materially, from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in the Company’s Annual Report on Form 20-F (File No. 001-34934) under the caption “Risk Factors”.

Company Contacts:

Gregory Zikos – Chief Financial Officer
Konstantinos Tsakalidis – Business Development, Investor Relations

Costamare Inc., Monaco
Tel: (+377) 93 25 09 40
Email: [email protected]

• Continued Clear Visual Evidence of Almost Completely Healed Skin After 6 weeks Treatment
• High Durability of Treatment Effect of QRX003 with Continuous Daily Dosing
• Patient Continues Not to Require Previously Necessary Medications
• With Patient’s Pruritus Almost Completely Eliminated, Patient Continues to Experience Zero Nightly Sleep Disturbance
• No Adverse Events Reported from 6 Weeks of Whole Body Treatment with QRX003
• Approval Received to Initiate Whole Body Testing of a Second Pediatric Patient

ASHBURN, Va., April 02, 2025 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. After 6 weeks of continued whole body application of QRX003, the subject’s skin remains almost completely healed demonstrating the durability of ongoing daily treatment with the product. In addition, the patient has continued to have no requirement for previously necessary medications such as antibiotics, antivirals, antihistamines and glucocorticoids. Importantly, with the patient’s pruritus or itch almost completely eliminated, she continues to experience zero nightly sleep disturbances without the need for any sedating medication, marking the first continuous period of uninterrupted sleep in the patient’s life. No adverse events have been reported to date after 6 weeks of whole body treatment with QRX003.

Quoin CEO Dr. Michael Myers, said, “As we continue to monitor the progress of this first patient to receive whole body application with QRX003, we are very pleased to announce that after 6 weeks of dosing we are seeing continued positive improvement and the patient’s skin is almost completely healed now. The patient continues to remain off previously needed medications including antihistamines, antivirals, and glucocorticoids, and she has not needed any antibiotics in the 6 weeks since the initiation of dosing with QRX003. Very importantly also, with her pruritus almost completely eliminated, the patient is still experiencing zero nightly sleep disturbances without the need for any sedating medications. For a majority of Netherton Syndrome patients, the continuous presence of chronically debilitating pruritus is the worst symptom of this disease and it severely impacts their ability to sleep or to even sit still for any period of time. Often heavy sedation is required to allow patients to sleep and sit still, which in turn has a major negative impact on their quality of life. The almost complete healing of the skin and the elimination of this chronically debilitating pruritus provides strong clinical evidence that QRX003 is successfully tackling the root causes of this disease and not merely providing symptomatic relief. Furthermore, I am very pleased to report that no adverse events have been reported after six full weeks of whole-body application of QRX003. Based on these positive results, approval has been received to initiate whole body application of QRX003 to a second pediatric Netherton patient. Testing is expected to commence in just a few weeks and we look forward to providing updates on both patients progress as we continue with our plans to further expand this study to include additional pediatric subjects.”

About Netherton Syndrome

Netherton Syndrome, a form of Ichthyosis, is a rare hereditary skin disorder caused by a mutation in the SPINK5 gene (serine protease inhibitor, Kazal Type 5) that leads to severe skin barrier defects and recurring infections, as well as a pronounced predisposition to allergies, asthma, and eczema. Patients often suffer from severe dehydration, chronic skin inflammation and stunted growth. Currently, there is no cure for Netherton Syndrome, nor are there any approved therapeutic treatments.

About QRX003

QRX003 is a topical lotion formulated with a proprietary delivery technology that contains a broad-spectrum serine protease inhibitor, whose mechanism of action is intended to perform the function of a specific protein called LEKTI. The absence of LEKTI in Netherton patients leads to excessive skin shedding, resulting in a highly porous and compromised skin barrier. QRX003 is designed to promote a more normalized skin-shedding process and the formation of a stronger and more effective skin barrier. For more information about Quoin’s current clinical trials please visit: https://www.nethertonsyndromeclinicaltrials.com/

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome,  Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.

Cautionary Note Regarding Forward Looking Statements

The Company cautions that statements in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances, such as “expect,” “intend,” “hope,” “plan,” “potential,” “anticipate,” “look forward,” “believe,” “may,” and “will,” among others. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: the potential efficacy of QRX003 as a treatment for Netherton Syndrome; testing expected to commence in a few weeks on a second pediatric patient; continue with our plans to further expand this study to include additional pediatric subjects; and Quoin’s products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome,  Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to deliver a safe and effective treatment for Netherton Syndrome; whether the Company’s studies successfully generate data that is sufficiently robust and comprehensive to support an NDA filing for QRX003 as an approved treatment for Netherton Syndrome; and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

For further information, contact:

Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
[email protected]

Investor Relations

PCG Advisory
Jeff Ramson
[email protected]
(646) 863-6341

Twenty Academic Affiliates Have Joined Compass Lexecon in the Past Six Months

Affiliates Bring Prior Experience at Government Agencies Including the FTC, FCC and SEC

Deep Expertise in a Wide Range of Areas, Including Merger Policy, Healthcare, AI, Finance, Venture Capital, Technology, Network Industries and Telecommunications

WASHINGTON, April 02, 2025 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that in the past six months 20 academic affiliates have joined its Compass Lexecon subsidiary, expanding client offerings in the Antitrust & Competition, Healthcare, Securities & Financial Markets, and Valuation practice areas, among others.

The new affiliates in Compass Lexecon’s Antitrust & Competition practice deepen the firm’s expertise in a wide range of areas, including competition and merger policy, telecommunications, entertainment and network industries, technology and innovation. These affiliates bring expertise in new and innovative economic fields, including field experiments, advanced econometric techniques, machine learning and AI, and the analysis of big data.

In the Compass Lexecon Healthcare and Life Sciences practice, three new affiliates bring expertise in health economics, industrial organization, cost-benefit analysis and data analytics. They have used cutting-edge tools, including AI, machine learning, and advanced statistical models, to analyze healthcare markets.

In the Securities & Financial Markets and Valuation practices, the new affiliates bring enhanced expertise in corporate finance, financial markets and products, venture capital, innovation financing and corporate governance. They further strengthen Compass Lexecon in the areas of bankruptcy and financial distress litigation and derivatives and structured finance.

“Compass Lexecon is a consulting firm built on a foundation of world-class academics,” said Compass Lexecon Chairman Daniel R. Fischel. “We are leaning into that tradition by adding talented academics who offer leading economic expertise and expert testimony capabilities and complement our deep bench of expert economists and professional staff.”

Antitrust & Competition

• Dr. Matthew Gentzkow is the Landau Professor in Technology and the Economy at Stanford University. He studies applied microeconomics with a focus on the economics of media and technology industries and these industries’ impacts on society and democracy. He received the 2014 John Bates Clark Medal, given by the American Economic Association to the American economist under the age of 40 who has made the most significant contribution to economic thought and knowledge. He is a member of the National Academy of Sciences, a fellow of the American Academy of Arts and Sciences, a fellow of the Econometric Society, a senior fellow at the Stanford Institute for Economic Policy Research and the Editor of American Economic Review: Insights. Dr. Gentzkow has presented his research to U.S. regulatory agencies, including the Department of Justice (“DOJ”), the Federal Trade Commission (“FTC”) and the Federal Communications Commission (“FCC”). He is also an experienced expert witness.
• Dr. John List is the Kenneth C. Griffin Distinguished Service Professor in Economics at the University of Chicago, and the Founder and Co-Director of the TMW Center for Early Learning + Public Health. Dr. List is a pioneer in the use of field experiments in economics and a recognized expert in industrial organization, labor economics and non-profit entities, among other areas. Dr. List is also an experienced expert witness and has provided expert testimony in the United States, Australia and Switzerland. He is the recipient of five honorary doctorate degrees.
• Dr. Ginger Jin is the Neil Moskowitz Professor of Economics at the University of Maryland, College Park, and previously served as Director of the Bureau of Economics at the FTC. She has deep expertise in analyzing mergers and acquisitions against the backdrop of emerging technologies and the use of big data in antitrust and consumer protection matters.
• Dr. Ali Hortaçsu is the William M. Ogden Distinguished Service Professor of Economics at the University of Chicago. Dr. Hortaçsu’s research is focused on using novel econometric techniques to analyze the efficiency of markets and he has developed pioneering econometric methods that can be applied to industrial organization, financial markets, energy markets, the internet and a variety of market clearing mechanisms including auctions, matching and consumer search. He is the author of the book, Structural Econometric Methods in Industrial Organization and Quantitative Marketing.
• Dr. William Rogerson is the Charles E. and Emma H. Morrison Chair of Market Economics at Northwestern University and former chief economist at the Federal Communications Commission. He is a leading antitrust and telecommunications expert whose research focuses on industrial organization, regulation, cost accounting and defense procurement. Dr. Rogerson has worked as a consultant for several government agencies, including the FTC, Institute for Defense Analysis, Logistics Management Institute, Office of the Secretary of Defense (Program Analysis and Evaluation), RAND Corporation and the DOJ.
• Dr. Luís Cabral is the Paganelli-Bull Professor of Economics and International Business and Chair of the Economics Department at the NYU Stern School of Business. His research focuses on the dynamics of firm competition from both the antitrust and strategy perspectives, and includes mergers, big tech, innovation and corporate reputation. Dr. Cabral has served as an expert witness and has advised numerous companies and government institutions, including the Federal Reserve Bank of New York, the Bank of Portugal and the European Commission. In addition, he is the author of Introduction to Industrial Organization, which has been translated into multiple languages and adopted by hundreds of universities globally.
• Dr. Daniel Spulber is the Elinor Hobbs Distinguished Professor of International Business and Professor of Strategy at the Kellogg School of Management, Northwestern University, and Professor of Law (Courtesy) at the Northwestern University Pritzker School of Law. He is a leading expert in antitrust and merger policy, platforms and two-sided markets, intellectual property, technology and innovation, and industrial organization. Dr. Spulber has provided expert testimony in state and federal courts as well as before the FTC, the International Trade Commission, the Copyright Royalty Board, the FCC, the Federal Energy Regulatory Commission (“FERC”), the Postal Rate Commission and state regulatory agencies.
• Dr. Peter Reiss is the MBA Class of 1963 Professor of Economics, Emeritus, at the Stanford University Graduate School of Business. He is a nationally renowned applied microeconomist with extensive expertise in industrial organization, econometrics and data science. His work has analyzed, among other topics, entry and competition in industries including financial markets, airlines, autos, retail and electricity. Dr. Reiss is an accomplished expert witness.
• Dr. Matthew Backus is a professor at the Haas School of Business and in the Economics Department at the University of California, Berkeley, where he teaches courses on antitrust, microeconomics and industrial organization. His research combines economic theory and empirical methods focused on antitrust, auctions, bargaining, communication and productivity. He is also involved in the development of tools that are used to distinguish empirically between theoretical models of behavior.
• Dr. Mehmet Ekmekci is a professor of economics at Boston College. His research focuses on industrial organization, platform economics and artificial intelligence. He has served as an expert in various matters involving auction design and competitive procurements in the satellite broadband industry and has consulted on mergers and government investigations in a wide variety of industries, including semiconductors, computer hardware, telecommunications and internet platforms.
• Dr. Aurelien Portuese is Research Professor and the Founding Director of the Competition & Innovation Lab at the George Washington University. His research focuses on antitrust law and economics in the United States and the EU. Dr. Portuese is also a consultant for the World Bank and is a member of the intergovernmental group of experts on Competition Law and Policy of the United Nations Conference on Trade and Development (“UNCTAD”).
• Dr. Kei Kawai is a professor at the University of Tokyo’s Graduate School of Economics and an associate professor at the University of California, Berkeley. He is a distinguished economist specializing in industrial organization and political economy. His research spans collusion detection in auction strategies, signaling behavior in credit markets and inferences from voting patterns.

Health Economics

• Dr. Matthew Grennan is an Associate Professor of Economics at Emory University. He specializes in using empirical and theoretical industrial organization models to analyze competition and innovation in healthcare and life-science markets. His research has examined how complex incentives and imperfect information affect how health technologies are developed, adopted and priced, and his work has been used in the development of business strategies and in policy debates regarding price transparency, relationships between physicians and industry, regulation of new products and antitrust. Dr. Grennan has served as an expert witness in numerous high-profile healthcare matters.
• Dr. Jonathan Kolstad is a professor at the Berkeley Haas School of Business, where he holds the Henry J. Kaiser Chair, and in the Economics Department at the University of California, Berkeley. Dr. Kolstad’s expertise lies at the intersection of health economics, industrial organization and public economics. Much of his research focuses on applying tools from behavioral economics, machine learning and AI to better understand behavior and market outcomes and to design policy and technology interventions to improve welfare.
• Dr. Craig Garthwaite is the Herman R. Smith Research Professor in Hospital and Health Services, a Professor of Strategy, and the Director of the Program on Healthcare at Kellogg School of Management. Dr. Garthwaite’s research focus includes pricing and innovation in the biopharmaceutical sector, the effect of changes in market size on investments in new product development, the evolution of precision medicine, the effect of expanded patent protection on pricing, and the relationship between health insurance expansions and drug prices. He has served as an expert witness in matters involving antitrust, the False Claims Act, transfer pricing, the impact of government policies and damages.

Securities, Financial Markets & Valuation

• Dr. Ilya Strebulaev is the David S. Lobel Professor of Private Equity and Professor of Finance at Stanford Graduate School of Business and a research associate at the National Bureau of Economic Research. He also is the founder and director of the Stanford GSB Venture Capital Initiative. Dr. Strebulaev is an expert in corporate finance, venture and angel capital, innovation financing, corporate innovation, private equity and financial decision-making. He also has extensive experience as an expert witness and has provided written and verbal testimony on behalf of a wide range of clients facing issues related to venture capital, valuation analysis, M&A disputes and other finance-related matters.
• Dr. Edward Morrison is a Professor of Law at Columbia Law School. He is an expert in corporate valuation, corporate restructuring, corporate and consumer bankruptcy, empirical analysis of contracts, and mortgage markets. Dr. Morrison has testified in high-profile cases involving large corporate bankruptcies and has served as an advisor and consultant to hedge funds, law firms and corporations.
• Dr. Audra Boone is a Professor of Finance and holder of the C.R. Williams Professorship in Financial Services in the Neeley School of Business at Texas Christian University. Prior to this position, she was a Senior Financial Economist at the U.S. Securities and Exchange Commission (“SEC”), working in the Office of Financial Intermediaries of the Division of Economic and Risk Analysis. She also served as a visiting scholar in the SEC’s Office of Litigation Economics working on issues related to allegations of securities fraud. She is also gaining experience and is in increasing demand as an expert witness in major litigation.
• Dr. Vyacheslav (Slava) Fos is a Professor of Finance and Hillenbrand Family Faculty Fellow at the Boston College Carroll School of Management. Dr. Fos is a leading corporate finance scholar and serves as a Research Associate for the National Bureau of Economic Research and a Research Fellow for the Centre for Economic Policy Research. He is currently a Visiting Professor at the Columbia University Graduate School of Business. Dr. Fos’s research has focused on multiple topics in corporate finance, including information transmission in financial markets, activist investors, corporate governance and insider trading. He has received numerous awards for his teaching and scholarship.
• Dr. Richard Lindsey specializes in quantitative analysis focused on risk and strategy development, including the uses and limitations of AI and machine learning technology for corporate management and board governance. He has also done extensive work in the areas of portfolio construction, risk management and the trading of securities. Dr. Lindsey previously served as Director of Market Regulation and Chief Economist at the SEC. He has also been a Professor of Finance at Yale University and is currently an adjunct professor of finance at NYU.

About Compass Lexecon

As a leading global economic consulting firm, Compass Lexecon has been involved in a broad spectrum of matters related to economics and finance – providing critical insight to its law firm, corporate, and government clients in legal and regulatory proceedings, strategic decisions, and public policy debates across all industries.

About FTI Consulting   
FTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 8,300 employees in 34 countries and territories as of December 31, 2024. The Company generated $3.69 billion in revenues during fiscal year 2024. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalized and independently managed. More information can be found at www.fticonsulting.com.  

FTI Consulting, Inc.  
555 12^th Street NW  
Washington, DC 20004  
+1.202.312.9100 

Investor Contact:  
Mollie Hawkes 
+1.617.747.1791 
[email protected] 

Media Contact:  
Matthew Bashalany 
+1.617.897.1545 
[email protected]